| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/28/2002 | US20020035998 Method for treatment of cancer and infectious disease |
| 03/28/2002 | US20020035996 Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery |
| 03/28/2002 | DE10135996A1 Identifying metastatic tumor cells and screening for antitumor agents, comprises hybridization to specific cDNA sequences |
| 03/28/2002 | DE10046029A1 Indazole Indazoles |
| 03/28/2002 | DE10043466A1 Non-irritating topical preparation for treating or preventing skin disorders, e.g. atopic dermatitis, psoriasis or aging symptoms, containing manganese salt to stimulate urea synthesis by keratinocytes |
| 03/28/2002 | CA2423315A1 Substituted amino-aza-cycloalkanes useful against malaria |
| 03/28/2002 | CA2423284A1 Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines |
| 03/28/2002 | CA2423181A1 Isolated nucleic acid molecules which encode a soluble il-tif/il-22 receptor or binding protein which binds to il-tif/il-22, and uses thereof |
| 03/28/2002 | CA2423104A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/28/2002 | CA2423090A1 Isolated human transporter proteins, nucleic acid molecules encoding them, and uses thereof |
| 03/28/2002 | CA2423071A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 03/28/2002 | CA2423044A1 Induction of exon skipping in eukaryotic cells |
| 03/28/2002 | CA2422964A1 Method for reducing toxicity of combined chemotherapies |
| 03/28/2002 | CA2422820A1 Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent |
| 03/28/2002 | CA2422671A1 Treatment of diabetes mellitus by inhibition of mitochondrial calcium/sodium antiporter |
| 03/28/2002 | CA2422631A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/28/2002 | CA2422568A1 Prognostic indicator |
| 03/28/2002 | CA2422549A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 03/28/2002 | CA2422541A1 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 03/28/2002 | CA2422215A1 B7-like molecules and uses thereof |
| 03/28/2002 | CA2421877A1 Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen |
| 03/28/2002 | CA2421865A1 Olfactory and pheromones g-protein coupled receptors |
| 03/28/2002 | CA2420862A1 Protein phosphatases |
| 03/28/2002 | CA2357901A1 Combination treatment for depression and anxiety |
| 03/28/2002 | CA2357853A1 Use of growth hormone secretagogues in conjunction with physical exercise |
| 03/27/2002 | EP1191099A1 Novel polypeptide and dna thereof |
| 03/27/2002 | EP1191097A1 Induction of exon skipping in eukaryotic cells |
| 03/27/2002 | EP1191036A2 Methods and compositions for diagnosing and treating disorders involving angiogenesis |
| 03/27/2002 | EP1190249A2 Compounds and methods to enhance raav transduction |
| 03/27/2002 | EP1190248A1 Screening methods for compounds which affect melanogenesis |
| 03/27/2002 | EP1190074A1 Recombinant anti-cd40 antibody and uses thereof |
| 03/27/2002 | EP1190065A2 Atp binding cassette transporter protein abc1 polypeptides |
| 03/27/2002 | EP1190057A1 Cloning and expression of a novel 5-ht4 receptor |
| 03/27/2002 | EP1190053A2 Mammalian calcium channels and related probes, cell lines and methods |
| 03/27/2002 | EP1190052A1 16405 receptor, a g-protein coupled receptor |
| 03/27/2002 | EP1190051A2 Human transport proteins |
| 03/27/2002 | EP1190050A2 Human transcriptional regulator proteins |
| 03/27/2002 | EP1190048A2 Novel candida albicans genes and proteins coded by said genes |
| 03/27/2002 | EP1189936A2 Use of eif4e binding agents in therapy |
| 03/27/2002 | EP1189926A2 Rapid dehydration of proteins |
| 03/27/2002 | EP1189895A1 Thiazole and oxazole derivatives and their pharmaceutical use |
| 03/27/2002 | EP1189887A2 Process for preparing 10,11-methanobenzosuberane derivatives |
| 03/27/2002 | EP1189749A1 Composite laminate and method for its production |
| 03/27/2002 | EP1189663A2 Synergy between low molecular weight heparin and platelet aggregation inhibitors, for preventing and treating thromboembolic disorders |
| 03/27/2002 | EP1189662A1 Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist |
| 03/27/2002 | EP1189645A2 Non-covalent bioconjugates useful for diagnosis and therapy |
| 03/27/2002 | EP1189641A2 HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 03/27/2002 | EP1189638A2 Pharmaceutical composition containing sibutramine and a lipase inhibitor |
| 03/27/2002 | EP1189637A2 Compositions for improving bioavailability of orally administered drugs |
| 03/27/2002 | EP1189629A2 Methods and reagents for treating glucose metabolic disorders |
| 03/27/2002 | EP1189628A1 Combination of tumor necrosis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation |
| 03/27/2002 | EP1189626A1 Method for preventing tumoral growth |
| 03/27/2002 | EP1189613A1 Method for the treatment of neurological or neuropsychiatric disorders |
| 03/27/2002 | EP1189611A1 Cancer therapy |
| 03/27/2002 | EP1189598A1 A method for the improvement of transport across adaptable semi-permeable barriers |
| 03/27/2002 | EP1189597A1 Oil-core compositions for the sustained release of hydrophobic drugs |
| 03/27/2002 | EP1189596A1 Pharmaceutical composition for nasally administering water-soluble active substances |
| 03/27/2002 | EP1047454A4 Methods of screening compounds useful for prevention of infection or pathogenicity |
| 03/27/2002 | EP0865421B1 Arylethanolamine derivatives and their use as agonists of atypical beta-adrenoceptors |
| 03/27/2002 | EP0831906B1 Treatment of t cell mediated autoimmune disorders |
| 03/27/2002 | EP0799056B1 Use of a nk-1 receptor antagonist and an opioid analgesic |
| 03/27/2002 | CN1342264A Heart abnormalities in vascular endothelial growth factor B(VEGF-B) deficient animals and methods relating to these heart abnormalities |
| 03/27/2002 | CN1342167A Low molecular weight peptide derivatives as inhibitors of laminin/nidogen interaction |
| 03/27/2002 | CN1342165A Neurotrophic growth factor |
| 03/27/2002 | CN1342096A Synergistic tumorcidal response induced by histamine |
| 03/27/2002 | CN1342091A Combinations of cardiovascular indications |
| 03/27/2002 | CN1342090A Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular disease |
| 03/27/2002 | CN1342089A Combinations of ileal bile acid transport inhibitors and cholestery ester transfer protein inhibitors for cardiovascular disease |
| 03/27/2002 | CN1342085A Inhibition of differentiation of cytotoxic T-cells by p-selecting ligand (PSGL) antagonists |
| 03/27/2002 | CN1342083A Uses of 1-amino-3-(N,N-dimethylamino)propylidene-1,1-bisphosphonic acid |
| 03/27/2002 | CN1342080A Use of 5-HT5-ligands in treatment of neurodegenerative and neuropsychiatric disturbances |
| 03/27/2002 | CN1342079A Treatment and prevention of reactive oxygen metablite-mediated cellular damage |
| 03/27/2002 | CN1342078A Use of 3-isoxazolidinones and hydroxylamine acids for treatment of infections |
| 03/27/2002 | CN1342077A Inhibition of formation of vascular hyperpermeability |
| 03/27/2002 | CN1342072A Method for preventing or delaying catheter-based revascularization |
| 03/27/2002 | CN1342070A Binding partners for 5-HT5 receptors for treatment of migraine |
| 03/27/2002 | CN1081624C Benzamide analogs, useful as PARP (ADP-ribosyltransferase, ADRPT) DNA repair enzyme inhibitors |
| 03/27/2002 | CN1081460C Use of medicine for reducing tissue damage associated with non-cardiac ischemia by aldose reductase inhibitor |
| 03/26/2002 | US6362392 Nude mouse model for the growth and treatment of human neurally-derived tumors |
| 03/26/2002 | US6362371 β2- adrenergic receptor agonists |
| 03/26/2002 | US6362316 Human metabotropic glutamate receptor subtype mGluR6 protein |
| 03/26/2002 | US6362237 Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception |
| 03/26/2002 | US6362236 Statin compound |
| 03/26/2002 | US6362234 Water-soluble prodrugs of propofol for treatment of migrane |
| 03/26/2002 | US6362207 Methods of treating viral infections with benzimidazoles |
| 03/26/2002 | US6362202 Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
| 03/26/2002 | US6362190 Administering compounds such as 3-(2-phenylethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylene -carboxamidomethylpyridi nyl)-2-pyrazinone, n'-((1-(aminoiminomethyl)4-piperidinyl) methyl)-n-(3,3-diphenylpropionyl)-l-proline amide |
| 03/26/2002 | US6362182 Hypotensive agents; anticholesterol agents; benign prostatic hypertropic |
| 03/26/2002 | US6362173 Methods for treating psychosis associated with cocaine addiction with glucocorticoid receptor antagonists |
| 03/26/2002 | US6362169 Antibacterial compositions with synergistic effect, drugs and remedies for digestive diseases containing the same, process for the production thereof and preparations associated therewith |
| 03/26/2002 | US6361970 A polypeptide encoding an isoleucyl trna synthetase; therapy and screening antibiotic compounds |
| 03/26/2002 | US6361967 Axor10, a g-protein coupled receptor |
| 03/26/2002 | US6361957 Assay for D-serine transport antagonist and use for treating psychosis |
| 03/26/2002 | US6361806 Composition for and method of topical administration to effect changes in subcutaneous adipose tissue |
| 03/26/2002 | US6361800 Vitamin and mineral supplements |
| 03/26/2002 | US6361760 Aerosol composition comprising tricyclic compound or pharmaceutically acceptable salt thereof, liquefied hydrofluoroalkane and medium-chain fatty acid triglyceride |
| 03/21/2002 | WO2002023199A2 Method, system, apparatus and device for discovering and preparing chemical compounds |
| 03/21/2002 | WO2002023184A1 Method for treatment of insulin resistance in obesity and diabetes |
| 03/21/2002 | WO2002022818A1 Human and rat pgc-3, ppar-gamma coactivations and splice variants thereof |
| 03/21/2002 | WO2002022809A2 PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST |